Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.

Br J Cancer · 2004 · PMC2409833 · PMID 15238986

Europe PMC DOI

hedged sentence

0.0970

closest p · 1.9× alpha

0.0970

boldest claim

The sentences

showed a trendP =0.097so close (0.05 < p ≤ 0.1)

The global quality of life score showed a trend in favour of the combination arm in cycle 3 ( P =0.097) but not in cycle 6 ( P =0.313).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.